The global hypereosinophilic syndrome drug market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). All the major players in the global hypereosinophilic syndrome drug market are involved in strategic alliances like acquisitions, partnerships, and collaborations to launch new drugs, to stay competitive in the market. Moreover, the rising US FDA approvals to the drugs developed by major pharmaceutical companies targeting hypereosinophilic syndrome also the factor that is creating significant scope for the market growth.
Browse the full report description of “Global Hypereosinophilic Syndrome drug Market Size, Share & Trends Analysis Report by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), and by Application (Hospital, Clinics, Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/hypereosinophilic-syndrome-drug-market
For instance, in March 2022, Bristol Myers Squibb announced that US FDA approved its OpdualagTM (nivolumab and relatlimab-rmbw), for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Besides, in September 2020, GlaxoSmithKline Plc. announced their approval of Nucala from USFDA that will be used for the treatment of hypereosinophilic syndrome for more than six months without an identifiable non-hematology cause in adults.
Moreover, in February 2019, AstraZeneca got USFDA approval of Orphan Drug Designation to Fasenra, a type of benralizumab drug for the treatment of hypereosinophilic syndrome. Similarly, in April 2019, Orphan Drug developed by Knopp Biosciences LLC, has been granted by the USFDA. its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2022
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Novartis AG, Kyowa Kirin Co. Ltd., and many more.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Hypereosinophilic syndrome drug Market Report Segment
By Type
By Application
Global Hypereosinophilic syndrome drug Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hypereosinophilic-syndrome-drug-market